(ACTU) Actuate Therapeutics - Ratings and Ratios
Clinical Trial Stage Oncology Compound
ACTU EPS (Earnings per Share)
ACTU Revenue
Description: ACTU Actuate Therapeutics
Actuate Therapeutics, Inc. is a biotechnology company listed on NASDAQ under the ticker symbol ACTU. As a common stock, it represents ownership in the company. The companys market capitalization stands at $174.61 million, indicating its size and investor recognition.
From a financial perspective, Actuate Therapeutics has a negative P/E ratio, suggesting that the company is currently not profitable or has negative earnings. This is not uncommon for biotech companies, which often invest heavily in research and development. The absence of a forward P/E ratio further indicates that the companys future earnings are not expected to be positive or are highly uncertain.
Key economic drivers for Actuate Therapeutics include the success of its R&D pipeline, regulatory approvals, and the ability to bring new therapies to market. Biotech companies like Actuate are often valued based on the potential of their drug candidates, the stage of their clinical trials, and the unmet medical need they address. Investors should monitor news on clinical trial results, FDA decisions, and partnerships or collaborations that could impact the companys prospects.
To evaluate Actuate Therapeutics performance, investors can track KPIs such as cash runway, burn rate, and the advancement of its drug pipeline through various stages of clinical trials. The companys ability to secure funding, either through equity financing, debt, or partnerships, is crucial for sustaining operations and advancing its research. Additionally, investors should be aware of the competitive landscape and how Actuates therapies compare to existing treatments or other drugs in development.
The stocks price movements and volatility, as indicated by its SMA and ATR, suggest that it has been experiencing fluctuations, potentially due to news or developments related to its clinical trials or industry trends. Investors should consider these technical indicators when assessing the timing of their investments. The average trading volume indicates a moderate level of liquidity, which is important for investors looking to buy or sell shares.
ACTU Stock Overview
| Market Cap in USD | 143m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2024-08-13 |
ACTU Stock Ratings
| Growth Rating | -37.9% |
| Fundamental | 38.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -29.2% |
| Analyst Rating | 4.67 of 5 |
ACTU Dividends
Currently no dividends paidACTU Growth Ratios
| Growth Correlation 3m | 62.7% |
| Growth Correlation 12m | -9.9% |
| Growth Correlation 5y | -12.5% |
| CAGR 5y | -16.96% |
| CAGR/Max DD 3y | -0.32 |
| CAGR/Mean DD 3y | -0.77 |
| Sharpe Ratio 12m | -0.40 |
| Alpha | 0.19 |
| Beta | 0.313 |
| Volatility | 83.54% |
| Current Volume | 24.6k |
| Average Volume 20d | 45.8k |
| Stop Loss | 6.5 (-7.7%) |
| Signal | -0.68 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-24.7m TTM) > 0 and > 6% of Revenue (6% = 28.6k TTM) |
| FCFTA -3.13 (>2.0%) and ΔFCFTA 936.0pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -3.26 (>3.0%) and CFO -22.7m > Net Income -24.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.73 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (19.6m) change vs 12m ago 0.59% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 10.97% (prev 0.0%; Δ 10.97pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1640 (EBITDA TTM -24.7m / Interest Expense TTM 18.7k) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 38.86
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -14.98% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 92.36 = -2.50 |
| 5. Debt/Ebitda -0.39 = -2.50 |
| 7. RoE data missing |
| 8. Revenue Trend data missing |
| 9. EPS Trend 77.13% = 3.86 |
What is the price of ACTU shares?
Over the past week, the price has changed by -17.27%, over one month by -14.67%, over three months by -15.89% and over the past year by -15.89%.
Is Actuate Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACTU is around 6.37 USD . This means that ACTU is currently overvalued and has a potential downside of -9.52%.
Is ACTU a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACTU price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.8 | 280% |
| Analysts Target Price | 26.8 | 280% |
| ValueRay Target Price | 7 | -0.7% |
Last update: 2025-09-12 04:30
ACTU Fundamental Data Overview
CCE Cash And Equivalents = 6.49m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -24.7m + Cost of Revenue 25.2m = 477.3k USD
P/B = 1977.797
Beta = None
Revenue TTM = 477.3k USD
EBIT TTM = -30.7m USD
EBITDA TTM = -24.7m USD
Long Term Debt = 421.9k USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 9.20m USD (from totalCurrentLiabilities, last quarter)
Debt = 9.62m USD (Calculated: Short Term 9.20m + Long Term 421.9k)
Net Debt = -6.49m USD (from netDebt column, last quarter)
Enterprise Value = 145.9m USD (142.7m + Debt 9.62m - CCE 6.49m)
Interest Coverage Ratio = -1640 (Ebit TTM -30.7m / Interest Expense TTM 18.7k)
FCF Yield = -14.98% (FCF TTM -21.8m / Enterprise Value 145.9m)
FCF Margin = -4577 % (FCF TTM -21.8m / Revenue TTM 477.3k)
Net Margin = -5172 % (Net Income TTM -24.7m / Revenue TTM 477.3k)
Gross Margin = -5172 % ((Revenue TTM 477.3k - Cost of Revenue TTM 25.2m) / Revenue TTM)
Tobins Q-Ratio = -1.01 (set to none) (Enterprise Value 145.9m / Book Value Of Equity -144.6m)
Interest Expense / Debt = 0.05% (Interest Expense 5062 / Debt 9.62m)
Taxrate = 21.0% (US default)
NOPAT = -30.7m (EBIT -30.7m, no tax applied on loss)
Current Ratio = 0.73 (Total Current Assets 6.69m / Total Current Liabilities 9.20m)
Debt / Equity = 92.36 (Debt 9.62m / last Fiscal Year total Stockholder Equity 104.2k)
Debt / EBITDA = -0.39 (Net Debt -6.49m / EBITDA -24.7m)
Debt / FCF = -0.44 (Debt 9.62m / FCF TTM -21.8m)
Total Stockholder Equity = -569.6k (last 4 quarters mean)
RoA = -354.2% (set to none)
RoE = unknown (Net Income TTM -24.7m / Total Stockholder Equity -569.6k)
RoCE = unknown (Ebit -30.7m / (Equity -569.6k + L.T.Debt 421.9k))
RoIC = unknown (NOPAT -30.7m, Invested Capital -569.6k, Ebit -30.7m)
WACC = 6.72% (E(142.7m)/V(152.3m) * Re(7.17%)) + (D(9.62m)/V(152.3m) * Rd(0.05%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 34.10 | Cagr: 4.35%
Discount Rate = 7.17% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -21.8m)
EPS Correlation: 77.13 | EPS CAGR: 11.8k% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0%
Additional Sources for ACTU Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle